Apollo Hospitals Enterprise Ltd

The aforementioned stake sale was executed through a block deal on the stock exchanges, at a price of Rs 7850 per share, a discount of nearly 1% to the closing price yesterday. Accordingly, the total value of the said transaction is Rs 1,489.33 crore The sale proceeds will be utilised to pare down outstanding debt of the Promoter Group. Subsequent to the sale, the Promoter Group holding in Apollo Hospitals will reduce to nearly 28% (from the current 29.3%) and pledged holdings of the Promoter Group (as a percentage of their total holding) will reduce from 13.1% to approximately 2%. The transaction fulfils a commitment made to investors to reduce the pledge,' the company said in a statement. The company further added that the Promoter Group does not have any plan of any further stake reduction in the foreseeable future. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The Group also offers telemedicine services in multiple countries, health insurance solutions, global project consultancy, and operates medical colleges, a nursing and hospital management college, and Medvarsity for e-learning. The company reported 41.80% surge in consolidated net profit to Rs 432.80 crore on 14.87% increase in revenue from operations to Rs 5,842.10 crore in Q1 FY26 over Q1 FY25. The scrip shed 0.20% to currently trade at Rs 7909.50 on the BSE. On the NSE, 2.29 lakh shares of the company were traded at the counter so far as against the three-month average trading volume of 4.78 lakh shares. On the BSE, 4437 shares of the company had changed hands at the counter as compared with the two-week average trading volume of 0.26 lakh shares. Powered by Capital Market - Live

Profit before tax (PBT) increased 35.51% YoY to Rs 582.70 crore in the quarter ended 30 June 2025. EBITDA grew by 26.22% to Rs 852 crore in Q1 FY26, up from Rs 675 crore in Q1 FY25. This includes Apollo 24/7 costs of Rs 121 crore during the quarter (including Rs 24 crore in non-cash ESOP charges), compared to Rs 150 crore in Q1 FY25. On segmenetal front, revenue from healthcare services rose 11% YoY to Rs 2,935 crore. Revenue from Apollo Health and Lifestyle (AHLL) stood at Rs 435 crore, up 19% YoY, while revenue from Apollo HealthCo reached Rs 2,472 crore, also up 19% YoY. As of 30 June 2025, Apollo Hospitals had 8,030 operating beds across its network (excluding AHLL and managed beds). Overall hospital occupancy was at 65%, compared to 68% in the same period last year. Dr. Prathap C Reddy, chairman, Apollo Hospitals Enterprise, said: I am proud to see the resilient comeback in the first quarter of FY26, building on the strong foundation of Q4 FY25. I am glad to inform you that Q1 FY26 has delivered another robust set of results, with revenue growth in the double digits at 15% YoY and continued improvement in margins. Our performance demonstrates the power and resilience of our integrated model of healthcare delivery with all three engines - our core divisions, Healthcare Services, Retail Healthcare & Diagnostics, and Digital & Pharma Distribution, contributing to our performance. Patient numbers across our network increased year-on-year, reflecting both the deeper penetration of our Centers of Excellence and the growing confidence of communities in our integrated care model. The quarter saw us announce our ambitious growth strategy to add over 4,300 beds in the next five years with an investment of over 7,600 crore. The first phase of 2,000 beds is already in progress. We have added an existing 200-bed hospital in Bengaluru and will also be establishing a 500-bed greenfield hospital in the suburbs of the city to bring the total bed strength in Bengaluru to 1,500 beds. In Hyderabad, we are adding 160 beds at our existing Jubilee Hills and Secunderabad facilities, and with the upcoming facility in Gachibowli, our bed strength in the city will increase to 1,400 beds. On the digital front, Apollo 24/7 achieved a quarterly GMVof over Rs 682 crore, sustaining the platform's momentum and signaling the continuing strong demand for teleconsultetions, lab and pharmacy deliveries. This performance builds on the platform's FY25 GMV of Rs. 3,007 crore, demonstrating our success in creating a seamless care continuum from home to hospital. The demerger of our digital health and pharmacy business, approved in the last quarter, is now in the implementation phase. This strategic move will enable focused capital allocation and sharper growth plans with dedicated management teams for both hospital operations and omnichannel healthcare ecosystem, a structure designed to maximize synergies while preserving the Apollo ethos of quality and trust. Preventive healthcare remains at the heart of our mission. Through the Al-based Apollo ProHealth platform, we have crossed 25Million health assessments this quarter alone, guiding individuals on personalized wellness journeys and strengthening early -detection pathways. Patient access continues to guide our investments. We expanded our 'Care-Within-Reach' financing programs to additional tier2 and tier3 markets, ensuring that advanced treatments remain accessible to a broad segment of the population. Our efforts on sustainability saw us launch 'Green Health' initiatives in Mumbai and Hyderabad, achieving a 20% reduction in energy consumption per patient day and using ecofriendly materials across new construction projects. Looking ahead, we anticipate continued double digit revenue growth for FY26, underpinned by new hospital openings in Patna and Jaipur slated for QJ, further digital innovation, and deepening partnerships with state governments to bolster community-based health initiatives. I remain confident that Apollo will set new benchmarks in clinical excellence, patient experience, and sustainable growth-true to our founding mission of enabling healthier, happier lives for all. Meanwhile, the board of directors of the company has approved an investment of an amount not exceeding a sum of Rs 85 million for acquiring 85,00,000 equity shares of Rs 10 each of Apollo Gleneagles PET-CT Private (AGPCL) from its existing shareholder, Parkway Healthcare (Mauritius) PTE, representing 50% of the total paid-up equity share of AGPCL. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The Group also offers telemedicine services in multiple countries, health insurance solutions, global project consultancy, and operates medical colleges, a nursing and hospital management college, and Medvarsity for e-learning. Additionally, it is supported by a dedicated research foundation. Powered by Capital Market - Live

Securities in F&O Ban: PG Electroplast, PNB Housing Finance, RBL Bank and Titagarh Rail Systems are banned from F&O trading on 13 August 2025. Upcoming Results: Bharat Petroleum Corporation, Pfizer, Deepak Nitrite, Brigade Enterprises, Aditya Birla Fashion and Retail, Samvardhana Motherson Internaional, AIA Engineering, Anupam Rasayan India, Astra Microwave Products, Avanti Feeds, Bhansali Engineering Polymers, Campus Activewear, CSB Bank, Dredging Corporation of India, Endurance Technologies Engineers India, Fiem Industries, Brainbees Solutions, Jubilant Foodworks, United Spirits will announce their result later today. Stocks to Watch: Apollo Hospitals Enterprise's consolidated net profit jumped 53.5% to Rs 389.60 crore on 13.1% increase in net sales to Rs 5592.20 crore in Q1 FY26 over Q1 FY25. ONGC's consolidated net profit fell 1.7% to Rs 9,804.07 crore on 3.5% decline in net sales to Rs 1,63,108.13 crore in Q1 FY26 over Q1 FY25. Jindal Steel & Power reported a 11.5% increase in consolidated net profit to Rs 1,493.97 crore in Q1 FY26 compared with Rs 1,340.15 crore in Q1 FY25. Net sales fell 9.7% YoY to Rs 12,294.48 crore during the quarter. Suzlon Energy 's consolidated net profit rose 7.3% to Rs 324.32 crore on 54.6% jump in net sales to Rs 3117.33 crore in Q1 June 2025 over Q1 June 2024. FSN E-commerce(Nykaa)'s consolidated net profit surged 141.9% to Rs 23.32 crore during the quarter, compared with Rs 9.64 crore in Q1 FY25. Net sales increased 23.4% YoY to Rs 2,154.94 crore in Q1 FY26. National Securities Depository (NSDL) reported a 7.6% jump in consolidated net profit to Rs 89.63 crore despite of 14.18% decline in net sales to Rs 312.03 crore in Q1 FY26 over Q4 FY25.Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 41.81% to Rs 432.80 crore in the quarter ended June 2025 as against Rs 305.20 crore during the previous quarter ended June 2024. Sales rose 14.88% to Rs 5842.10 crore in the quarter ended June 2025 as against Rs 5085.60 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales5842.105085.60 15 OPM %14.5813.27 - PBDT797.40607.40 31 PBT582.70430.00 36 NP432.80305.20 42 Powered by Capital Market - Live

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live

The board of AHEL and its subsidiary, Apollo HealthCo granted in-principle approval for the demerger of Omnichannel Pharma and Digital Health business. The proposed structure enables direct access of omni-channel pharmacy and digital health business to the shareholders of AHEL. For every 100 shares of AHEL, the shareholders of AHEL will receive 195.2 shares of the new company, Apollo Healthtech enabling their direct participation in the value unlock. The proposed transaction will result in the creation of the largest, integrated omni channel healthcare eco-system with a FY25 revenue of approximately Rs 16,300 crore ($ 1.9 billion) in FY25. The Apollo Healthtech is expected to achieve a revenue run rate of Rs 25,000 crore ($2.9 billion) by FY27. Upon the effectiveness of the Scheme, Apollo Healthtech will become an Indian owned and controlled company (IOCC) and it will apply for listing on the stock exchanges. The listing is expected within 18 to 21 months. AHEL will retain 15% stake in the Apollo Healthtech to ensure an integrated, seamless, and comprehensive healthcare offering across the patient lifecycle. Upon becoming an IOCC, the Apollo Healthtech also proposes to consolidate the front-end pharmacy business by acquiring the remaining 74.5% stake in Apollo Medicals (AMPL), which owns 100% of APL. Dr Prathap C Reddy, chairman, Apollo Hospitals Group, said Today's developments mark the beginning of the next chapter of Apollo Hospitals' relentless mission to bring healthcare of world-class standards within the reach of every individual. The omnichannel pharmacy business and integrated digital healthcare ecosystem will be a unique model to enable access to high-quality healthcare for millions of Indians. What Apollo Hospitals achieved for the creation of the private healthcare industry in India, this new entity will create for the digitally forward generation of tomorrow. We have the opportunity to make a positive difference to their lives and partner in their wellness pursuits. I wish both the teams all the best as they enter uncharted territory with infinite potential. Suneeta Reddy, managing director, Apollo Hospitals Enterprise said, Apollo has always focused on growth, reach, and scale. We have carefully built our formats-of-care around the consumer at the centre. This comprehensive integrated network, overlaid with a strong digital layer, will allow us to create an impact of magnitude greater than could be achieved with a single format of care. AHEL will continue its focus on outstanding healthcare delivery, while the New Entity will accelerate its efforts on deepening customer engagement and penetration, with clear capital allocation outlays, growth plans and management teams driving both. Together, we will generate unparalleled value for the consumer, while making sure that all synergies and network effects stay intact, rooted in the Apollo ethos of quality and trust. Shobana Kamineni, executive chairperson, Apollo HealthCo said, The New Entity, once integrated, will be a truly customer-focused healthcare leader, with capabilities across the value chain. Delivering medicines seamlessly from more than 7,000 physical stores, online delivery platform serving over 19,000 pincodes, with Keimed ensuring supply chain integrity, our aspiration is that we will serve over 100 million Indians with trusted quality and availability. With each business expected to record healthy rates of growth, we will continue to be the leader in this sector. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The company reported 53.5% jump in consolidated net profit to Rs 389.60 crore on 13.1% increase in revenue from operations to Rs 5,592.20 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Profit before tax (PBT) jumped 40% YoY to Rs 515.50 crore in the quarter ended 31st March 2025. EBITDA grew 20% to Rs 769.9 crore in Q4 FY25 as compared with Rs 640.5 crore in Q4 FY24. EBITDA margin stood at 13.8% in Q4 FY25 as against 13% in Q4 FY24. Revenue from healthcare services increased 10% YoY to Rs 2,822 crore, revenue from Apollo health and lifestyle (AHLL) stood at Rs 394 crore, up 11% YoY and revenue from Apollo healthCo was at Rs 2,376.3 crore, up 17% YoY. As on March 31, 2025, Apollo Hospitals had 8,025 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% as against 65% in the same period in the previous year. On full year basis, the company's consolidated net profit climbed 60.9% to Rs 1,445.90 crore on 14.3% increase in revenue from operations to Rs 21,794 crore in FY25 over FY24. Dr. Prathap C Reddy, chairman, Apollo Hospitals Enterprise, said: 'At Apollo, our mission has always gone beyond treating illness-it is about enabling every individual to live a healthier, happier life. FY25 was a defining year. With revenues crossing approximately Rs 20,000 crore and Healthcare Services surpassing around Rs 11,000 crore, we are humbled by the trust placed in us across India and beyond. To address the rising burden of non-communicable diseases, we are intensifying our preventive care mission. Through Apollo ProHealth, we are set to globally launch pioneering wellness programs that redefine the healthcare landscape - shifting the focus from reactive treatment to proactive, preventive care. We are committed to growth and to the enhancement of our care toucbpoints, with new hospitals to be commissioned this year in Pune, Kolkata, Hyderabad, Bangalore and Delhi NCR - and several more in varying stages of development. These state-of-the-art facilities will be equipped with cutting-edge medical technology, reinforcing our commitment to delivering world-class care at scale. Our over Rs 8,000 crore investment over the next five years will add over 4,300 beds, with the first phase of - 2,000 beds already in progress-bringing advanced care closer to communities across India. Apollo Pharmacies crossed 6,600 stores this year and Apollo 24/7 commenced distribution of Insurance products to increase access to care.' Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share with a face value of Rs 5 each for FY25. The board has fixed the record date as Tuesday, 19th August 2025. The dividend, if declared at the annual general meeting will be paid on or before 10th September 2025. Further, the company's board has approved a proposal to purchase a land parcel admeasuring 2.53 acres at Sarjapur, Bengaluru for setting up a 500-bed greenfield multi-specialty hospital, at an estimated overall cost of Rs 944 crore. Additionally, the company will also be acquiring a 200 bedded hospital located in the vicinity of the land parcel identified for setting up the 500 bed greenfield hospital. The overall cost of acquiring the existing hospital facility (expandable to 200 beds immediately) and upgrading the existing hospital infrastructure is estimated to be Rs 285 crore. Apollo Hospitals Enterprise has established a strong presence across the healthcare ecosystem, encompassing hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. The Group also offers telemedicine services in multiple countries, health insurance solutions, global project consultancy, and operates medical colleges, a nursing and hospital management college, and Medvarsity for e-learning. Additionally, it is supported by a dedicated research foundation. The counter shed 0.68% to end at Rs 6,878.20 on the BSE.Powered by Capital Market - Live

Apollo Hospitals Enterprise announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Apollo Hospitals Enterprise announced that the Annual General Meeting(AGM) of the company will be held on 29 August 2025.Powered by Capital Market - Live

Profit before tax (PBT) jumped 40% YoY to Rs 515.50 crore in the quarter ended 31st March 2025. EBITDA grew 20% to Rs 769.9 crore in Q4 FY25 as compared with Rs 640.5 crore in Q4 FY24. EBITDA margin stood at 13.8% in Q4 FY25 as against 13% in Q4 FY24. Revenue from healthcare services increased 10% YoY to Rs 2,822 crore, revenue from Apollo health and lifestyle (AHLL) stood at Rs 394 crore, up 11% YoY and revenue from Apollo healthCo was at Rs 2,376.3 crore (up 17% YoY) As on March 31, 2025, Apollo Hospitals had 8,025 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% as against 65% in the same period in the previous year. On full year basis, the company's consolidated net profit climbed 60.9% to Rs 1,445.90 crore on 14.3% increase in revenue from operations to Rs 21,794 crore in FY25 over FY24. Dr. Prathap C Reddy, chairman, Apollo Hospitals Enterprise, said: 'At Apollo, our mission has always gone beyond treating illness-it is about enabling every individual to live a healthier, happier life. FY25 was a defining year. With revenues crossing ~approximately Rs 20,000 crore and Healthcare Services surpassing around Rs 11,000 crore, we are humbled by the trust placed in us across India and beyond. To address the rising burden of non-communicable diseases, we are intensifying our preventive care mission. Through Apollo ProHealth, we are set to globally launch pioneering wellness programs that redefine the healthcare landscape - shifting the focus from reactive treatment to proactive, preventive care. We are committed to growth and to the enhancement of our care toucbpoints, with new hospitals to be commissioned this year in Pune, Kolkata, Hyderabad, Bangalore and Delhi NCR - and several more in varying stages of development. These state-of-the-art facilities will be equipped with cutting-edge medical technology, reinforcing our commitment to delivering world-class care at scale. Our over Rs 8,000 crore investment over the next five years will add over 4,300 beds, with the first phase of - 2,000 beds already in progress-bringing advanced care closer to communities across India. Apollo Pharmacies crossed 6,600 stores this year and Apollo 24/7 commenced distribution of Insurance products to increase access to care.' Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share with a face value of Rs 5 each for FY25. The board has fixed the record date as Tuesday, 19th August 2025. The dividend, if declared at the annual general meeting will be paid on or before 10th September 2025. Further, the company's board has approved a proposal to purchase a land parcel admeasuring 2.53 acres at Sarjapur, Bengaluru for setting up a 500-bed greenfield multi-specialty hospital, at an estimated overall cost of Rs 944 crore. Additionally, the company will also be acquiring a 200 bedded hospital located in the vicinity of the land parcel identified for setting up the 500 bed greenfield hospital. The overall cost of acquiring the existing hospital facility (expandable to 200 beds immediately) and upgrading the existing hospital infrastructure is estimated to be Rs 285 crore. Apollo Hospitals has a robust presence across the healthcare ecosystem, including hospitals, pharmacies, primary care & diagnostic clinics and several retail health models. The Group also has telemedicine facilities across several countries, health insurance services, global projects consultancy, medical colleges, medvarsity for e-learning, colleges of nursing and hospital management and a research foundation. The counter shed 0.68% to end at Rs 6,878.20 on the BSE.Powered by Capital Market - Live